How a major discovery can become a public health failure when used subotptimally: lessons from early nirsevimab implementation.

ABSTRACT:

Background

In this Debate, based on our clinical data from the "pre-nirsevimab" and "first year of nirsevimab implementation" bronchiolitis seasons, we challenge the validity of policy decisions that led to partial immunization coverage of eligible newborns and infants during the 2024-25 season in Italy.

Main body

Starting with a pre-nirsevimab prospective cohort of 780 newborns, we documented that 84 (9.2%) were diagnosed with acute bronchiolitis (45 of them (5.8% of the cohort) were RSV positive. 44 patients (5.6%) were hospitalized due to bronchiolitis, of which 7 (0.9%) patients were admitted to the Pediatric Intensive Care Unit. Among hospitalized, 31 infants (70%) had RSV infection. Secondly, we evaluated the impact on bronchiolitis admissions during the first year of

SUBMITTER: Buonsenso D 

PROVIDER: S-EPMC12619484 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature